# Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-con-020dd9a5
Ticker: MDGL
Company: Madrigal
Source: Madrigal
Published: 2026-09-02 12:00 EST
## Summary

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in...

## Article Body
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page . A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com .

Investor Contact Tina Ventura, IR@madrigalpharma.com

Media Contact Christopher Frates, media@madrigalpharma.com
## Recent Company News
- 2026-09-02 12:00 EST — [Madrigal Pharmaceuticals to Participate in the  2026 Cantor Global Healthcare Conference](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-2026-cantor-global-healthcare-con-020dd9a5) — Source: Madrigal
- 2026-08-20 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-bfb00a5a) — Source: Madrigal
- 2026-08-12 12:00 EST — [Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors](https://biopharmsignal.com/news/MDGL/madrigal-appoints-john-c-reed-m-d-ph-d-to-its-board-of-directors-88756ec9) — Source: Madrigal
- 2026-08-06 20:05 EST — [Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-announces-grants-of-inducement-awards-under-nasdaq-list-52cfb9fa) — Source: Madrigal
- 2026-08-06 12:00 EST — [Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference](https://biopharmsignal.com/news/MDGL/madrigal-pharmaceuticals-to-participate-in-the-canaccord-genuity-45th-annual-gro-04739d27) — Source: Madrigal
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)